Loading organizations...

§ Private Profile · Nashville, TN, USA
Clinical-stage biotech developing mGlu4 PAMs for Parkinson's disease and other neurological disorders.
Appello Pharmaceuticals is a clinical-stage biotechnology company based in Nashville, Tennessee, that develops novel therapeutics for Parkinson's disease and other neurological disorders. Operating as a spin-out from Vanderbilt University, the enterprise focuses on creating positive allosteric modulators targeting the mGlu4 receptor to alleviate symptoms without the severe side effects of standard treatments. The organization advanced its lead drug candidate, AP-472, into Phase 1 clinical trials in late 2021 to assess its efficacy in treating nervous system conditions. The firm has raised over 29 million dollars in total funding, including Series A and Series B rounds, backed by Deerfield Management, Mountain Group Partners, TriStar Health Partners, and the Michael J Fox Foundation. Brian Laden, Craig Lindsley, and P Jeffrey Conn founded the venture in 2017 to commercialize innovative neuroscience research from the Warren Center for Neuroscience Drug Discovery.
Appello Pharmaceuticals has raised $16.0M across 1 funding round.
Appello Pharmaceuticals has raised $16.0M in total across 1 funding round.
Appello Pharmaceuticals has raised $16.0M in total across 1 funding round.
Appello Pharmaceuticals's investors include Mountain Group Partners, William Slattery.
Appello Pharmaceuticals is a clinical-stage neurology therapeutics company developing innovative drugs for neurological disorders, particularly Parkinson's disease.[1][3][4] Its lead candidate, AP-472, targets motor symptoms like rigidity and immobility in preclinical Parkinson's models, showing enhanced effects with levodopa, and advances through clinical trials via collaboration with Vanderbilt University's Warren Center for Neuroscience Drug Discovery.[1][3] Founded in 2018 in Nashville, Tennessee, the company has raised $29.01M in funding, including a Series B round of $13.5M three years ago, serving patients with central nervous system disorders amid rising global prevalence.[1][2][3]
Appello Pharmaceuticals was founded in 2018 in Nashville, Tennessee, emerging from groundbreaking research at Vanderbilt University's Warren Center for Neuroscience Drug Discovery (WCNDD), where its lead program originated.[1][3] The company's president and founder leads the effort, supported by key executives including the President & CEO and Chief Medical Officer, driving translation of academic discoveries into clinical drug candidates.[2][3] Early traction built on preclinical success of AP-472 in Parkinson's models, securing investments from firms like Mountain Group Partners, Deerfield Management, and TriStar Health Partners, totaling $29.01M by its Series B stage.[1]
Appello rides the wave of neuroscience breakthroughs unlocking brain research, translating them into drugs amid a global surge in neurological disorders over the past 25 years, where disease burden outpaces treatments.[1][4] Timing aligns with exploding research from human brain understanding, enabling a potential paradigm shift this decade in CNS therapies—critical as aging populations amplify Parkinson's and similar conditions.[2][4] Favorable market forces include investor interest (e.g., Series B funding) and clinical momentum, influencing the ecosystem by validating academic-industry hybrids that speed innovation in underserved neurology.[1][3]
Appello's clinical progression of AP-472 positions it for pivotal trial readouts and potential partnerships, capitalizing on neuroscience momentum to expand its pipeline beyond Parkinson's.[1][3] Trends like AI-driven drug discovery and CNS breakthroughs will shape its path, potentially amplifying influence through larger trials or acquisitions by big pharma seeking neurology assets.[4] As a Nashville-based leader, Appello exemplifies how targeted therapeutics can redefine neurological care, building on its Vanderbilt roots to deliver the paradigm shift in patient outcomes it champions.[3][4]
Appello Pharmaceuticals has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in June 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2018 | $16M Series A | Mountain Group Partners, William Slattery | — | Announced |